Some numbers mark a turning point. They show that something meaningful is happening. Today, we have reached one of those moments: 50,000 patients have now joined the Boli community.
This number is more than symbolic. It represents a growing movement: tens of thousands of people, across countries and backgrounds, navigating a metabolic journey that is personal, complex, and often misunderstood. At Boli, we feel the weight of this responsibility and the pride that comes with it.
Why 50,000 matters
This milestone signals that metabolic health is entering a new era. The rise of GLP-1 receptor agonists has opened an unprecedented therapeutic window. But one truth remains unchanged: medication alone is not enough.
Patients need support. They need clear explanations. They need a place where they can ask questions, understand their symptoms, and feel seen. And most importantly, they need to connect with others who are going through the same journey. This is what the Boli community stands for.
A community built on support, science, and real-life experience
What has emerged around Boli goes far beyond a digital tool. It has become a living ecosystem where patients share their experiences, questions, struggles, and wins. Their feedback directly shapes our scientific and clinical work. Real-world patterns help us understand what happens outside controlled studies. And every contribution strengthens the collective experience.
We see this every day: when a patient is no longer alone, their journey changes. Confidence rises. Treatment adherence improves. Understanding deepens.
What 50,000 patients means for Boli
This milestone accelerates everything we do.
It strengthens the development of our digital therapeutic, currently undergoing certification as a medical device, dedicated to supporting patients starting GLP-1 receptor agonist treatments.
It fuels our work on a more adaptive and more personalized AI, capable of understanding a patient’s metabolic profile, their treatment progression, their side effects, and their lifestyle context.
It enriches a growing body of real-world evidence built from lived experience rather than theory.
It helps us continuously improve each part of the Boli platform: content, tools, monitoring, and guidance.
50,000 patients is momentum. It is the sign that what we are building matters.
This is only the beginning
The GLP-1 wave is just beginning. More and more patients will need guidance, clarity, and structured support. We believe the future of metabolic care will be shaped by the combination of effective medication and high-quality, science-driven, empathetic support.
The Boli community is already one of the largest in the field of GLP-1 support. But each patient matters. Each story matters. Each step forward matters.
Thank you
To everyone who shares their feedback.
To those who ask questions.
To those who progress at their own pace.
To all patients who joined Boli to better understand and manage their treatment.
Thank you for being 50,000.
Thank you for your trust.
Thank you for helping us build the digital therapeutic that will support the next generation of GLP-1 patients.
This journey is only beginning, and it is stronger because we are building it together.
